The National Institute for Health & Clinical Excellence (NICE) have issued a draft decision not to recommend lapatinib (Tyverb) for use on the NHS. A final decision is expected later this year. Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This will be disappointing for some women with advanced breast cancer. Breakthrough hopes that if further results from clinical trials are positive this decision will be reviewed in future.
More...
Linear Mode
